Update
$Summit Therapeutics(SMMT.US$ Summit Therapeutics Announced Data For Ivonescimab In Advanced Non-small Cell Lung Cancer, That Is Being Presented At The 2024 European Lung Cancer Congress
Benzinga· 3 mins ago
Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at baseline – 23% achieved a complete response
All patients who did not achieve an intracranial response demonstrated stable disease or non-progression by RANO criteria irrespective of cohort
Median intracranial PFS of 19.3 months observed across combined cohorts of ivonescimab administered as monotherapy or in combination with chemotherapy
No cases of intracranial bleeding were observed in these patients with brain metastases
Detailed safety and anti-tumor activity updates from Phase II trial for ivonescimab plus chemotherapy in multiple NSCLC settings, including 1L squamous NSCLC
Benzinga· 3 mins ago
Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at baseline – 23% achieved a complete response
All patients who did not achieve an intracranial response demonstrated stable disease or non-progression by RANO criteria irrespective of cohort
Median intracranial PFS of 19.3 months observed across combined cohorts of ivonescimab administered as monotherapy or in combination with chemotherapy
No cases of intracranial bleeding were observed in these patients with brain metastases
Detailed safety and anti-tumor activity updates from Phase II trial for ivonescimab plus chemotherapy in multiple NSCLC settings, including 1L squamous NSCLC
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
